PRESS RELEASE published on 04/06/2023 at 23:00, 3 years 4 months ago MRNA-4157/V940, an Investigational Personalized MRNA Cancer Vaccine, in Combination With Keytruda(R) (Pembrolizumab), Receives Prime Scheme Designation From the European Medicines Agency for Adjuvant Treatment of Patients With High-Risk Stage III/IV Melan
PRESS RELEASE published on 03/30/2023 at 13:00, 3 years 4 months ago Moderna Finalizes Agreement with the Government of the Republic of Kenya to Establish an mRNA Manufacturing Facility
PRESS RELEASE published on 03/24/2023 at 12:30, 3 years 4 months ago Moderna to Host Fourth Annual Virtual Vaccines Day on April 11, 2023
PRESS RELEASE published on 03/23/2023 at 12:02, 3 years 4 months ago Moderna and Generation Bio Announce Strategic Collaboration to Develop Non-Viral Genetic Medicines
PRESS RELEASE published on 03/14/2023 at 22:40, 3 years 4 months ago Moderna Announces Phase 2 Data on mRNA-4157/V940, an Investigational mRNA Personalized Cancer Vaccine, to be Presented at the 2023 AACR Annual Meeting
PRESS RELEASE published on 03/10/2023 at 17:00, 3 years 5 months ago Moderna Outlines Commitment to Corporate Growth and Announces U.S. Expansion in 2023
PRESS RELEASE published on 02/28/2023 at 13:30, 3 years 5 months ago Moderna to Present at Cowen's 43rd Annual Health Care Conference
PRESS RELEASE published on 02/23/2023 at 13:00, 3 years 5 months ago Moderna Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Updates
PRESS RELEASE published on 02/22/2023 at 22:05, 3 years 5 months ago Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination With KEYTRUDA(R) (pembrolizumab), was Granted Breakthrough Therapy Designation by the FDA for Adjuvant Treatment of Patients With High-Risk Mela
PRESS RELEASE published on 02/22/2023 at 13:00, 3 years 5 months ago Moderna And Life Edit Therapeutics Enter Strategic Collaboration to Accelerate the Development of Novel In Vivo Gene Editing Therapies
Published on 08/13/2026 at 09:05, 1 hour 6 minutes ago Battery X Metals Appoints Lithium-Ion Battery and Electric Vehicle Entrepreneur William Fan as President to Advance Development of Its Patent-Pending Lithium-Ion Battery Rebalancing Technology Platform and Corporate Growth Initiatives
Published on 08/13/2026 at 08:00, 2 hours 11 minutes ago Battery X Metals Maintains Y Lithium Project Claims in Good Standing and Evaluates Phase I Exploration Program
Published on 08/13/2026 at 07:30, 2 hours 41 minutes ago Battery X Metals Announces Closing of Second Tranche of Private Placement to Advance Corporate Growth Initiatives
Published on 08/12/2026 at 23:30, 10 hours 41 minutes ago CCL Industries Announces Record Results for 2026 Second Quarter
Published on 08/13/2026 at 10:05, 5 minutes ago Thunes Expands Web3 Infrastructure with EURC to Enable Instant Euro Treasury Funding
Published on 08/13/2026 at 10:00, 11 minutes ago BENO Holding AG Acquires and Leases Light Industrial Property in the Nuremberg Metropolitan Area
Published on 08/13/2026 at 09:52, 18 minutes ago Gledhow Investments plc: £400,000 Subscription, Strategic Repositioning and Proposed Board Appointments
Published on 08/13/2026 at 09:17, 53 minutes ago EQS-Adhoc: InTiCa Systems SE: InTiCa Systems SE resolves to prepare the change from the regulated market (Prime Standard) to the Scale segment of the Frankfurt Stock Exchange
Published on 08/11/2026 at 17:45, 1 day 16 hours ago DAMARTEX / Droits de vote bruts et réels au 31 juillet 2026
Published on 08/11/2026 at 17:40, 1 day 16 hours ago Infotel : Déclaration des transactions sur actions propres réalisées du 3 au 7 août 2026 dans le cadre du programme de rachat d’actions
Published on 08/10/2026 at 18:00, 2 days 16 hours ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Published on 08/10/2026 at 18:00, 2 days 16 hours ago AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/07/2026
